Weekly Symptom Monitoring Linked to 5-Month Survival Gain in Lung Cancer

Why This Study Matters

Lung cancer remains one of the leading causes of cancer-related mortality worldwide, and routine follow-up during treatment typically relies on periodic clinic visits that can miss symptom deterioration in between. A 2017 JAMA study previously reported, in a mixed advanced-cancer population, that structured electronic patient-reported outcome (PRO) symptom monitoring was associated with improved overall survival compared with usual care — a finding that helped motivate disease-specific trials such as SYMPRO-Lung.

SYMPRO-Lung's own original 1-year report, published in JAMA Network Open in 2024, found significant improvements in health-related quality of life, but only a non-significant trend toward survival benefit at that earlier timepoint (overall survival hazard ratio 0.80, 95% CI 0.55–1.15, for the active-alert subgroup versus control). The post-hoc analysis covered here extends follow-up to a median of 50 months and reports, for the first time, a statistically significant long-term overall survival association.

Study Design

SYMPRO-Lung was a multicentre, stepped-wedge, cluster-randomised clinical trial conducted across 14 medical centres in the Netherlands. All participating hospitals began in a control period using standard of care, then crossed over, according to a computer-generated randomisation sequence, to an intervention period in which patients completed weekly online symptom assessments for one year. The trial's original primary outcome was health-related quality of life, reported separately; the analysis featured here is a post-hoc evaluation of long-term overall and progression-free survival, with overall survival as its primary endpoint.

Patient Population

Eligible patients were aged 18 years or older with stage I–IV lung cancer (new-onset or recurrent; cytologically or histologically confirmed, or radiologically suspected) who were starting new treatment. Of the 515 patients enrolled between October 24, 2019 and September 16, 2021, 446 (87%) were included in this post-hoc survival analysis (230 male, 216 female). The remaining 69 patients (13%) were excluded because they had not consented to use of their data in follow-up research, or because linkage to the Netherlands Cancer Registry could not be established.

Primary Endpoint: Overall Survival

Using Cox mixed-effects modelling adjusted for age, sex, stage, histology, ECOG performance status, systemic treatment line, and a random effect for site clustering, the intervention-to-treat comparison showed a 5-month difference in median overall survival favoring the monitored group. Progression-free survival did not differ significantly between groups.

Subgroup Analyses and Safety

The published abstract for this post-hoc analysis does not report subgroup-specific hazard ratios, confidence intervals, or P values by stage, histology, or treatment line — only the overall intention-to-treat comparison, adjusted for these variables as covariates, is reported. SYMPRO-Lung also evaluated a symptom-monitoring care workflow rather than a drug or device therapy, and the available abstract does not report adverse-event data. Both are genuine data-availability limitations of the abstract-only source used for this article, not omissions introduced here.

Interpretation and Broader Context

The authors conclude that weekly PRO symptom monitoring was associated with a meaningful improvement in long-term overall survival among patients with stage I–IV lung cancer, with a median overall survival difference of five months. Because this is a post-hoc analysis of survival — a secondary endpoint added after the trial's original quality-of-life primary endpoint was already reported — and because the P value (0.049) sits at the edge of conventional significance thresholds, the finding is best read as hypothesis-generating evidence supporting the value of routine PRO symptom monitoring in lung cancer care, rather than a confirmatory demonstration of a survival-extending intervention.

Weekly PRO symptom monitoring was associated with meaningful improvement in long-term overall survival among patients with stage I-IV lung cancer.
— Study abstract, The Lancet Oncology, September 11, 2026

What Comes Next

The study authors note that these findings support implementing routine PRO symptom monitoring within standard lung cancer care. Prospective trials specifically powered for long-term survival, along with formal subgroup and mediator analyses, would be needed to confirm a causal survival benefit.

Limitations

This is a post-hoc, secondary survival analysis layered onto a trial whose original primary endpoint — quality of life — was already reported separately, which raises the risk the survival signal reflects multiplicity rather than a prespecified hypothesis. The adjusted overall survival P value of 0.049 sits at the edge of conventional statistical significance, and progression-free survival, the companion efficacy measure, showed no significant difference between arms. The published source is an abstract rather than the full text, so it does not report subgroup-specific statistics or any adverse-event data, and 69 of 515 enrolled patients (13%) were excluded from this analysis for consent or registry-linkage reasons, which could introduce selection bias not addressable with abstract-level data.